



# The GRACIOUS Framework

## For Grouping and Read-Across of Nanoforms

Vicki Stone



[v.stone@hw.ac.uk](mailto:v.stone@hw.ac.uk)

[www.h2020gracious.eu](http://www.h2020gracious.eu)



---


Project no. 760840

## Presentation structure

- An overview of the GRACIOUS Framework
  - Examples grouping hypotheses
  - Example Integrated Approaches to Testing and Assessment
  - Similarity
  - Database links
  - Quality
  - Blueprint
-


### Project Aim

Generate a **Framework** to enable practical application of **grouping**, and subsequent **read-across** of nanomaterials (NMs)/nanoforms (NFs).



"Substances whose **physicochemical, toxicological and ecotoxicological** properties are likely to be similar or follow a regular pattern as a result of structural **similarity** may be considered as a **group**" (REACH, Annex XI, 1.5).

# Framework Design Process



# Stakeholder engagement



- EU policy makers
  - E.g. EC
- EU regulatory bodies
  - E.g. ECHA, EFSA, JRC
- European national government bodies
  - E.g. RIVM, NRCWE, BfR
- Non-EU regulatory bodies
  - E.g. US EPA, Health Canada
- Industry bodies
  - E.g. NIA, ECETOC and BIAC
- Industry
  - E.g. BASF, Black Diamond
- Consultants
  - E.g. Yordas, Blue Frog

# Thank you



Contents lists available at [ScienceDirect](#)

## Nano Today

journal homepage: [www.elsevier.com/locate/nanotoday](http://www.elsevier.com/locate/nanotoday)



## A framework for grouping and read-across of nanomaterials-supporting innovation and risk assessment

[Vicki Stone<sup>a,\\*</sup>](#), [Stefania Gottardo<sup>b</sup>](#), [Eric A.J. Bleeker<sup>c</sup>](#), [Hedwig Braakhuis<sup>c</sup>](#), [Susan Dekkers<sup>c</sup>](#), [Teresa Fernandes<sup>a</sup>](#), [Andrea Haase<sup>d</sup>](#), [Neil Hunt<sup>e</sup>](#), [Danail Hristozov<sup>f</sup>](#), [Paula Jantunen<sup>b</sup>](#), [Nina Jeliaskova<sup>g</sup>](#), [Helinor Johnston<sup>a</sup>](#), [Lara Lamon<sup>f</sup>](#), [Fiona Murphy<sup>a</sup>](#), [Kirsten Rasmussen<sup>b</sup>](#), [Hubert Rauscher<sup>b</sup>](#), [Araceli Sánchez Jiménez<sup>h</sup>](#), [Claus Svendsen<sup>i</sup>](#), [David Spurgeon<sup>j</sup>](#), [Socorro Vázquez-Campos<sup>j</sup>](#), [Wendel Wohlleben<sup>k</sup>](#), [Agnes G. Oomen<sup>c</sup>](#)

<sup>a</sup> NanoSafety Research Group, Heriot-Watt University, Riccarton, Edinburgh EH14 4AS, UK

<sup>b</sup> European Commission, Joint Research Centre (JRC), Ispra, Italy

<sup>c</sup> National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands

<sup>d</sup> German Federal Institute for Risk Assessment (BfR), Department of Chemical and Product Safety, Berlin, Germany

<sup>e</sup> Yordas Group, Lancaster Environment Centre, Lancaster University, Lancaster, UK

<sup>f</sup> Green Decisions, Venice, Italy

<sup>g</sup> Ideacon Ltd, Sofia, Bulgaria


<sup>h</sup> Institute of Occupational Medicine (IOM), Research Avenue North, Edinburgh EH14 4AP, UK

<sup>i</sup> UK Centre for Ecology & Hydrology, Maclean Building, Benson Lane, Crowmarsh Gifford, Wallingford, OX10 8BB, UK


<sup>j</sup> LEITAT Technological Center, Barcelona, Spain

<sup>k</sup> BASF SE, Dept. Material Physics and Dept. of Experimental Toxicology & Ecology, Ludwigshafen, Germany

## Simple form



## Detailed form




# Justification criteria are purpose specific. i.e. less stringent for SbD than for RA or legislation



# Using the Framework for Read-Across

Use grouping to identify source NFs

Target NF ↔ Potential source NFs and non-NFs



Lacks data

Data available

Consider similarities and differences in group for 'What they are' and 'Exposure route/compartiment'

Generate Read-across hypothesis for a specific endpoint

Compare source and target materials –  
Where they go  
What they do

Substantiation of Read-across hypothesis

Generate additional data if needed –  
physicochemical, *in silico*,  
*in vitro* and/or *in vivo*

Assessment of Read-across hypothesis

Assess whether target NF is of lower or similar risk compared to the source NF or non-NF

Justification for read-across from source material


## Using the Framework for Innovation

- During innovation, **safe(r)-by-design** approaches help to avoid expensive, time consuming, unexpected problems with new **nano-enabled products**
- Grouping and Read-across can be used during the innovation process
  - E.g. aid prioritization of lower hazard candidate NFs while ensuring product functionality



**INNOVATION**


## Getting started



## Along Nano-enabled produce life cycle

### Steps to integrate release & exposure:

- Select key elements to describe release & exposure
- Identify main determinants of release & exposure
- Generate grouping hypothesis based on release & exposure
- Provide Integrated Approaches to Testing and Assessment of these hypotheses




NF identity	LCS	Release	Emission	Transmission	Exposure
<b>NFs in powder form</b> <ul style="list-style-type: none"> <li>% of NF</li> <li>Size</li> <li>Shape</li> <li>Moistness</li> </ul>	<b>Manufacture</b> <ul style="list-style-type: none"> <li>Chemical processes</li> <li>Physical process</li> <li>...</li> </ul>			<b>Inhalation</b> <ul style="list-style-type: none"> <li>Dilution/ventilation</li> <li>Diffusion</li> <li>Gravitational settling</li> <li>Aggregation/agglomeration</li> <li>Sedimentation</li> </ul>	<ul style="list-style-type: none"> <li>Exposure pathway</li> <li>Concentration of NF</li> <li>Exposure duration and frequency</li> <li>Loading into the bio-compartment (skin, alveolar, ...)</li> <li>Migration rate</li> <li>Use of personal protective equipment</li> </ul>
<b>NFs in liquid suspension/dispersion</b> <ul style="list-style-type: none"> <li>% of NF</li> <li>Size</li> <li>Shape</li> <li>Vapour pressure</li> <li>Viscosity</li> </ul>	<b>Formulation</b> <ul style="list-style-type: none"> <li>Mechanical treatments (drilling, grinding, sanding, ...)</li> <li>Thermal treatments</li> <li>Spraying application</li> <li>...</li> </ul>	<b>Use Industrial site</b> <ul style="list-style-type: none"> <li>Pouring</li> <li>Mixing</li> <li>Stirring</li> <li>...</li> </ul>	<b>Risk managements measures (at the source)</b> <ul style="list-style-type: none"> <li>Containment</li> <li>LEV</li> </ul>	<b>Dermal</b> <ul style="list-style-type: none"> <li>Migration rate (rubbing contact)</li> </ul>	
<b>NFs in solid matrix</b> <ul style="list-style-type: none"> <li>% of NF</li> <li>Size</li> <li>Shape</li> <li>Type of matrix</li> <li>Location of NFs</li> <li>Dispersion of NFs</li> <li>Bond between NFs and matrix</li> </ul>	<b>Professional use</b> <ul style="list-style-type: none"> <li>Application into the skin</li> <li>Wearing</li> </ul>	<b>Consumer use</b> <ul style="list-style-type: none"> <li>Washing</li> <li>Weathering</li> <li>Leaching</li> </ul>	<b>Article design</b> <ul style="list-style-type: none"> <li>Use conditions</li> <li>Precautionary measure</li> </ul>	<b>Inadvertent digestion</b> <ul style="list-style-type: none"> <li>Transfer efficiency (Surface-hand and hand to perioral)</li> </ul>	
	<b>Service Life</b> <ul style="list-style-type: none"> <li>Incineration</li> <li>Landfilling</li> <li>...</li> </ul>		<b>Risk managements measures (at the source)</b> <ul style="list-style-type: none"> <li>...</li> </ul>	<b>Dissolution</b> <ul style="list-style-type: none"> <li>Precipitation</li> <li>Adsorpt./desorpt.</li> <li>(Bio)chemical transformation</li> <li>Dispersion</li> </ul>	<ul style="list-style-type: none"> <li>Exposure duration and frequency</li> <li>Environmental compartments</li> </ul>

## Along Nano-enabled produce life cycle

### Release & exposure components identified in the basic step:

- Likelihood of release & exposure
- Physicochemical form of NF during release & exposure
- Environmental compartments affected
- Exposed populations
- Exposure routes



NF identity	LCS	Release	Emission	Transmission	Exposure
<b>NFs in powder form</b> <ul style="list-style-type: none"> <li>% of NF</li> <li>Size</li> <li>Shape</li> <li>Moistness</li> </ul>	Manufacture	<ul style="list-style-type: none"> <li>Chemical processes</li> <li>Physical process</li> <li>...</li> </ul>		<b>Inhalation</b> <ul style="list-style-type: none"> <li>Dilution/ventilation</li> <li>Diffusion</li> <li>Gravitational settling</li> <li>Aggregation/agglomeration</li> <li>Sedimentation</li> </ul>	<ul style="list-style-type: none"> <li>Exposure pathway</li> <li>Concentration of NF</li> <li>Exposure duration and frequency</li> <li>Loading into the bio-compartment (skin, alveolar, ...)</li> <li>Migration rate</li> <li>Use of personal protective equipment</li> </ul>
<b>NFs in liquid suspension/dispersion</b> <ul style="list-style-type: none"> <li>% of NF</li> <li>Size</li> <li>Shape</li> <li>Vapour pressure</li> <li>Viscosity</li> </ul>	Formulation	<ul style="list-style-type: none"> <li>Mechanical treatments (drilling, grinding, sanding, ...)</li> <li>Thermal treatments</li> <li>Spraying application</li> <li>...</li> </ul>	Risk managements measures (at the source)	<b>Dermal</b> <ul style="list-style-type: none"> <li>Migration rate (rubbing contact)</li> </ul>	
	Use Industrial site	<ul style="list-style-type: none"> <li>Pouring</li> <li>Mixing</li> <li>Stirring</li> <li>...</li> </ul>	Containment LEV	<b>Inadvertent digestion</b> <ul style="list-style-type: none"> <li>Transfer efficiency (Surface-hand and hand to perioral)</li> </ul>	
	Professional use				
<b>NFs in solid matrix</b> <ul style="list-style-type: none"> <li>% of NF</li> <li>Size</li> <li>Shape</li> <li>Type of matrix</li> <li>Location of NFs</li> <li>Dispersion of NFs</li> <li>Bond between NFs and matrix</li> </ul>	Consumer use	<ul style="list-style-type: none"> <li>Application into the skin</li> <li>Wearing</li> </ul>	Article design Use conditions Precautionary measure		
	Service Life	<ul style="list-style-type: none"> <li>Washing</li> <li>Weathering</li> <li>Leaching</li> </ul>		<b>Dissolution</b> <ul style="list-style-type: none"> <li>Precipitation</li> <li>Adsorpt./desorpt.</li> <li>(Bio)chemical transformation</li> <li>Dispersion</li> </ul>	Exposure duration and frequency Environmental compartments
	End of Life	<ul style="list-style-type: none"> <li>Incineration</li> <li>Landfilling</li> <li>...</li> </ul>	Risk managements measures (at the source)		

## Presentation structure

- An overview of the GRACIOUS Framework
  - Examples grouping hypotheses
  - Example Integrated Approaches to Testing and Assessment
  - Similarity
  - Database links
  - Quality
  - Blueprint
-

Grouping is hypothesis driven



## Hypothesis template

- The basic information triggers a hypothesis
- There are many ways to word and formulate a hypothesis
- To provide guidance to the user GRACIOUS has developed a Hypothesis Template

Purpose and context	
Life Cycle	What they are?
	Where they go?
	What they do?

**Posters Topic 4** Risk assessment, risk management and risk governance

**ID 1076** - A Template for Hypothesis Generation to Facilitate Grouping and read-Across of Nanomaterials and Support Risk decision-Making

Grouping is hypothesis driven



## Hypothesis template

The Framework guides users to **pre-defined** hypotheses if appropriate.

- Often encompass both fate and hazard
- Based upon the literature and available data
  - 17 for human hazard
  - 23 for environmental hazard

If no predefined hypotheses are appropriate, the Framework guides generation of a **user-defined** hypothesis.

---



Grouping is hypothesis driven



## Example Hypotheses - Human

**Respirable NFs showing quick dissolution:** Following **inhalation** both NFs and constituent ions or molecules may contribute to toxicity, but there is no concern for accumulation. Toxicity (also) depends on the location of the ionic or molecular release.

**NFs with a very slow dissolution rate:** Following **oral** exposure NFs will maintain nanospecific activity that may drive translocation across the GIT wall, subsequent biopersistence in the body and systemic toxicity in secondary organs.

**NFs with constituent substance(s) or degradation products classified for dermal irritation or sensitization:** **Dermal** exposure to the NFs may result in dermal irritation or sensitization.

---

Grouping is hypothesis driven



## Example Hypotheses - Environment

NFs with a quick dissolution rate in environmentally relevant aquatic media: Following aqueous exposure lethal and sub-lethal toxicity to representative aquatic species is driven by the fate and toxicity characteristics of the dissolution products.

NFs with a chemical coating that is lost from the NF surface following exposure in soil compartment can be grouped: Fate and toxicity of the exposure relevant NF can be considered similar to a non-coated analogous NF in soil compartment


Bioavailable NFs with a very slow dissolution rate in sediment can be grouped: Following sediment exposure, NFs in this group will maintain nano-specific activity and can cause lethal and sub-lethal toxicity to representative benthic species.

---

# Pre-defined hypothesis

- Span different exposure scenarios and hence exposure routes

- Inhalation
- Ingestion
- Dermal
- Air
- Aqueous
- Sediment
- Soil




## Presentation structure


- An overview of the GRACIOUS Framework
  - Examples grouping hypotheses
  - Example Integrated Approaches to Testing and Assessment
  - Similarity
  - Database links
  - Quality
  - Blueprint
-

## IATA Decision Tree Format

- Aligns with OECD recommendations (OECD 2017)
- Decision Nodes are measurable with defined criteria to ensure a clear 'yes' or 'no' answer
- Identify points of departure where you may deviate from, and therefore reject, the grouping hypothesis
- Combines and integrates all relevant existing evidence and guides the targeted generation of new data, where required, to support evidence-based grouping.



## IATA structure




## Data Matrix

- The IATA provides the evidence needed to test the hypothesis
- Data is compiled into a data matrix which includes assessment of similarity for all endpoints


Source	NF1	NF2
✓	✗?	✓
		✓?


Respirable, biopersistent, rigid HARN:

Following **inhalation** exposure and translocation of HARN to the pleura, mesothelioma development can occur.









# Tiered testing strategy



## Purposes of Grouping

Safe(r) by Design

Adoption of  
precautionary measures

Regulatory purposes

INCREASING CONFIDENCE IN  
GROUPING

### Decision Node Question

#### Tier 1

Review existing data

*In Silico*  
*In Chemico*  
Simple *in vitro*

#### Tier 2

Review existing data

Complex *in vitro*  
models

#### Tier 3

Review existing data

*In vivo* models

Inhalation Exposure is expected

Can NF deposit in the distal lung?



Does the NF dissolve very slowly in lung fluid?



Does the NF dissolve very slowly in phagocytic cells?

Translocation to the pleural cavity?

Is NF length > 5µm?



Is NF fibrous, rigid with a needle-like structure?




Does NF cause frustrated phagocytosis?



Group NF as respirable, biopersistent, and with potential to cause mesothelioma

# Building a tiered testing strategy



# Tiered Testing Strategy

## HARN



Can NF deposit in the distal lung?	Does the NF dissolve very slowly in lung lining fluid?	Does the NF dissolve very slowly in lysosomal fluid?	Is NF length >5µm?	Is the NF fibrous, rigid with needle-like morphology?	Does the NF cause frustrated phagocytosis?	Does NF stimulate a similar inflammation response to source material?
------------------------------------	--	--	--------------------	---	--	---

Review existing data

Tier 1						
Review existing data sets						
Estimation of $D_{ae}$ from NF size measurements by TEM/SEM and density measurement	Batch dissolution test in lung lining fluid (pH 7.4) or Dissolution in continuous flow system in lung lining fluid (pH 7.4)	Batch dissolution test in lysosomal fluid (pH 4.5) or Dissolution in continuous flow system in lysosomal fluid (pH 4.5)	NF size measurements by TEM/SEM	Measure diameter of NF by TEM	Inflammasome activation: <ul style="list-style-type: none"> <li>IL-1<math>\beta</math> release</li> <li>CathepsinB activity and /or release</li> <li>Lysosomal Disruption</li> </ul>	Inflammation potency: <i>in vitro</i> testing using cell lines <ul style="list-style-type: none"> <li>Acute Endpoints: <ul style="list-style-type: none"> <li>Cytotoxicity</li> <li>Cytokine release</li> </ul> </li> </ul>

**Tier 1**

Batch dissolution test in lysosomal fluid (pH 4.5) or Dissolution in continuous flow system in lysosomal fluid (pH 4.5)

Tier 2						
Review existing data sets						
Measurement of MMAD by cascade impactor from an airborne dispersion of the material	Lung deposition modelling: <ul style="list-style-type: none"> <li>Multiple Particle Path Deposition Model</li> <li>FIBROS</li> </ul>	Durability in cellular systems	NF size measurements by TEM/SEM from an airborne dispersion of the material	Measurement of flexural rigidity by dynamic scanning electron microscopy	<i>In vitro</i> granuloma formation	<i>In vitro</i> incubation with co-culture models of macrophages and mesothelial cells or 3D microtissue models <ul style="list-style-type: none"> <li>Acute Endpoints: <ul style="list-style-type: none"> <li>Cytokine release</li> </ul> </li> <li>Chronic: <ul style="list-style-type: none"> <li>Granuloma formation</li> </ul> </li> </ul>

Review existing data

**Tier 2**

Durability in cellular systems

Tier 3						
Review existing data sets						
		Lung burden measurement after <i>in vivo</i> instillation or inhalation studies		'Biologically stiff' NF determined experimentally by morphological assessment and size measurements after <i>in vitro</i> incubation with macrophages.		Intraperitoneal/ Intrapleural instillation: <ul style="list-style-type: none"> <li>Acute Endpoint: <ul style="list-style-type: none"> <li>inflammation,</li> </ul> </li> <li>Chronic: <ul style="list-style-type: none"> <li>Fibrotic lesion</li> <li>Mesothelioma</li> </ul> </li> </ul>

Review existing data

**Tier 3**

Lung burden measurement after *in vivo* instillation or inhalation studies

Where they go

What they do

## Persistent and unstable NFs in aquatic compartment:



Following aquatic exposure, NF are deposited to **sediments** where lethal and sub-lethal toxicity to sediment species can occur.

**Purpose:** Targeted testing, regulatory

**Context:** Aquatic environments

### Input from life cycle

Release to aquatic environment

### What they are?

NFs with a slow/partial dissolution rate that have a high affinity for natural colloids in aquatic compartments.


### Where they go?


Removed from the aquatic compartment and deposited to sediment compartments (via sedimentation).

### What they do?

Persist in sediment compartments resulting in lethal and sub-lethal toxicity to representative sediment species.

Persistent and unstable NFs in aquatic compartment:  
Following aquatic exposure, NF are deposited to  
**sediments** where lethal and sub-lethal toxicity to  
sediment species can occur.





CONTEXT SWITCH

**Persistent bioavailable NFs:** Following sediment exposure, NFs will maintain nano-specific activity and can cause lethal and sub-lethal toxicity to representative sediment species.

Sediment exposure is expected



Sediment exposure is expected

Is the dissolution of bioavailable NF very slow?

NO

Hypothesis rejected: Bioavailable NF concentration in sediment is sensitive to dissolution. Consider alternative sediment hypothesis.

YES

Do NFs remain unchanged in sediment without chemical transformation into “new” NFs?

NO

Hypothesis is rejected: Characterise/model the transformation process(es) and assess the “new” NFs.

YES

Hypothesis accepted: Bioavailable NF will maintain nano-specific activity in sediment with potential to cause lethal and sub-lethal toxicity to representative sediment species

Does the NF have a similar toxic effect compared to the source material?

# Tiered Testing Strategy

## Tier 1

Review existing data

Acute sediment toxicity assays  
e.g. *Vibrio fischeri* microtox assay,  
*Caenorhabditis elegans* sediment  
toxicity assay.




<https://www.imscience.com/medicine/scientists-increase-worms-lifespan-by-500/>

## Tier 2

Review existing data

Chronic single-species sediment  
toxicity tests  
e.g. *Lumbriculus variegatus*,  
*Chironomus riparius* OECD TG



<https://blogs.uef.fi/ecotox/2016/06/22/hands-on-research-with-chironomus-riparius/>

## Tier 3

Review existing data

Chronic single-species assays w/aged  
NF.  
Microcosm/mesocosm



## Presentation structure

- An overview of the GRACIOUS Framework
  - Examples grouping hypotheses
  - Example Integrated Approaches to Testing and Assessment
  - Similarity
  - Database links
  - Quality
  - Blueprint
-

## Approaches to similarity

- There are several methods being developed to assess similarity
  - Similarity by **bandings** (fixed)
    - E.g. OECD TG318 proposes banding of dispersion stability
      - <10% | 10 to 50% | 50 to 90% | >90%
    - Fixed/bandings require clear thresholds which are difficult to justify
    - Fixed thresholds lead to problems with cases that lie close to the threshold/cut-off.
  - Similarity by **relative difference** (floating)
    - E.g. to be in Group B, ROS production by NFs must be within a 5-fold range of each other (or a target NF) according to protocol x.x.1
    - Reduce issues associated with NFs that are close to a threshold/cut-off
    - Requires consideration of what dissimilarity is acceptable between NFs to allow them to be grouped
-

# Approaches to similarity

- The GRACIOUS Framework generates a **data matrix** containing several relevant endpoints
    - A **similarity assessment** needs to be generated across all NFs **per endpoint/assay**
  - To facilitate a similarity assessment even a single property often requires data reduction
    - A size distribution → D50 median size;
    - dose-response → BMD20 or EC50 or ...
  - “Acceptable dissimilarity” must consider:
    - measurement accuracy
    - biological relevance of dissimilarity
    - dose metrics
      - E.g. Surface area vs Mass
  - **Calibration** of a case study tier 1 data with existing tier 3 data is required
-

## Similarity historical example

# Biologically relevant x-fold differences: fiber biodissolution



As Kdis increases from 13 to 329 (25-fold) the pathogenicity becomes qualitatively different.

Pathogenicity is moderately different at k=72 (5-fold)

If values are **> 5-fold different**, then the values are **not similar** (close to a biological threshold of HARN effects).


Table 65. Lung biopersistence, in-vitro dissolution and pathogenicity of selected fibres from inhalation studies in rats

Fibre		Biopersistence: fibres > 20 µm in length; lung clearance rates				In-vitro dissolution (k <sub>dis</sub> ) at pH 7.4 (pH 4.5)*	Pathogenicity (chronic inhalation)		Reference
		Slower pool (T½)	WT½ (days)	90% clearance (T <sub>90</sub> , days)			Lung fibrosis	Thoracic tumours	
Amosite	Asbestos	1160	418	2095	Hesterberg <i>et al.</i> (1998a)	< 1	+	+	McConnell <i>et al.</i> (1999)
Crocidolite <sup>d</sup>	Asbestos	0	817	2770	Hesterberg <i>et al.</i> (1996a)	< 1	+	+	McConnell <i>et al.</i> (1994)
MMVF32	E Glass wool	179	79	371	Hesterberg <i>et al.</i> (1998a)	9 (7)	+	+	Davis <i>et al.</i> (1996a)
RCF1a <sup>a</sup>	Refractory ceramic fibre	88	55	227	Hesterberg <i>et al.</i> (1998a)	3	+	+	Mast <i>et al.</i> (1995a,b)
MMVF33	475 Glass wool	155	49	240	Hesterberg <i>et al.</i> (1998a)	12 (13)	+	+/- <sup>b</sup>	Davis <i>et al.</i> (1996a); McConnell <i>et al.</i> (1999)
MMVF21	Rock (stone) wool (96)	613	91	206	Hesterberg <i>et al.</i> (1996a)	20 (72)	+	–	McConnell <i>et al.</i> (1994)
MMVF21	Rock (stone) wool (98)	95	67	264	Hesterberg <i>et al.</i> (1998a)				
MMVF10 <sup>d</sup>	901 Glass wool (96)	0	37	123	Hesterberg <i>et al.</i> (1996a)	300 (329)	–	–	Hesterberg <i>et al.</i> (1993)
MMVF10.1 <sup>c</sup>	901 Glass wool	30	14.5	69	Hesterberg <i>et al.</i> (2002)		–	–	McConnell <i>et al.</i> (1999)

IARC MONOGRAPHS  
ON THE EVALUATION  
OF CARCINOGENIC  
RISKS TO HUMANS


# Biologically relevant x-fold differences: NF biodissolution

- Assess dissolution in
  - lung lining simulant fluid (LSF) pH7.4
  - Phagolysosomal simulant fluid (PSF) pH4.5
- Tested 17 NFs of silica, organic and inorganic pigments
- Benchmarked against
  - TiO<sub>2</sub>** - very slow dissolution rate
  - BaSO<sub>4</sub>** - partial dissolution
  - ZnO** - quick dissolution.
- Assessed dissimilarity of dissolution halftime.



# Biologically relevant x-fold differences: NF biodissolution

- Dissolution divides the colloidal silica NFs into
  - group with Al-doping
  - group w/o Al doping.
  - NM200 remains separate
- Shape & silane treatment less important!



half time	Silica_std	Silica_anis_std	Silica_Al	Silica_anis_Al	Silica_silane	SiO2 NM200
LSF pH 7.4						
Silica_std		1.96	7.28	5.78	1.26	8.29
Silica_anis_std	1.16		3.72	2.95	1.55	4.24
Silica_Al	1.07	1.08		1.26	5.78	1.14
Silica_anis_Al	1.03	1.13	1.04		4.59	1.44
Silica_silane	1.08	1.26	1.16	1.12		8.29
SiO2 NM200	9.03	7.76	8.41	8.74	9.77	
PSF pH 4.5						

similar

dissimilar





# Pairwise similarity matrix



## Case study: FRAS assay



Surface dose



Mass dose



# GRACIOUS eNanoMapper

## Using existing and new data



The screenshot shows the ENM eNanoMapper web interface. At the top, there's a navigation bar with links: Home, About, Projects, FAIR Data, and Help. Below this is a "Welcome to the Nanosafety Data Interface" message, stating that the interface provides aggregated findable, accessible, interoperable and reusable (FAIR) data to support safety assessment of nanomaterials. A row of logos follows, including Public (NanoReg, ENM), Restricted access (NanoReg2, Gov4Nano, gracious, SBD4Nano), and others like caLIBRAte, RISK GONE, PATROLS, and BIO RIMA. The main content area shows the "H2020 GRACIOUS - eNanoMapper database" with license information for NANOREG, ENPRA, MARINA, NANOTEST, and GRACIOUS. On the left, a sidebar lists "Projects (80533)" with a filter box and buttons for ENPRA, GRACIOUS, MARINA, NANOGRUVUR, NANOREG, NanoTest, and SANOWORK. Below the sidebar, there are expandable sections for "Study providers (6692)", "Nanomaterial type (6693)", "Nanomaterial (6693)", "GRACIOUS materials (3701)", "Protocols (19195)", and "Protocol annotation (1203)". The main panel shows tabs for "Hits list", "Selection", "Predefined Queries", and "Export". The "Selection" tab is active, displaying "Select dataset to export" with buttons for "Filtered entries" and "Selected entries". Below this is "Select export/report type" with a dropdown menu. The dropdown menu is open, showing options: "Study results - all values, minimal metadata" (selected), "Study results", "Materials and all study results", "Materials information", "Study results - all values, minimal metadata", "NanoREG physchem template (under development)", "Study report - new format (under development)", "Compact data report", "Summary report: basic essentials only" (highlighted in blue), "Summary report: Number of data points - materials on rows", "Summary report: Number of data points - materials on columns", "Summary report: Method, cells, project", and "Summary report: Methods, endpoints, project".

## Data to support GRACIOUS Framework

- Phys-chem
- Cell viability, oxidative stress, reactivity
- Harmonized templates and terminology
- Nanomaterial similarity
- Range of output formats
- All data is used by the blueprint test environment

# Release and exposure Templates with quality scores



← → ↻ search.data.enanomapper.net/projects/gracious/datatemplates/exposure\_release/

gracious Home Project Search Summary Template Wizard ▾ Help ▾ [n10705013] Log out

## Template Wizard : exposure and release

H2020 GRACIOUS - eNanoMapper database

Assay

ECR: Environmental Consumer Release ▾

Download template

Excel template download

ECHA Use Descriptors

Life Cycle stage

Sector of use

Product category

Manufacture ▾

Manufacture of furniture ▾

Nothing selected ▾

Process category

Environment Release category

Article category

Technical Function

Nothing selected ▾

Nothing selected ▾

Nothing selected ▾

Ablative, Abrasive, Absorbent, ▾

Activity characteristics

Source Domain

Activity Name

Project partner

Project Work package

Nothing selected ▾

(ultra) High pressure (sand) ▾

WP2-Lifecycle: Human exp ▾

Materials table - all materials will be available for selection in the Excel file

Show 10 ▾ entries

ERM	ID	Name	Type	Supplier

Ablative ✓  
Abrasive ✓  
Absorbent ✓  
Adhesion promoter ✓  
Adsorbent ✓  
Aerating and deaerating agents  
Antiadhesive  
Alloying element  
Anticaking agent  
Anticondensation agent  
Antifreeze agent  
Antioxidant  
Antiredeposition agent



The templates are free to use under the licence agreement **Creative Commons - Share alike**.

If you intend to use these templates, as such or modifying them, please acknowledge the primary source mentioning "GRACIOUS Release and Exposure Templates".

Dear User,

This introductory page serves as a guide, if needed, to be integrated with the information included in the "read-me-first" PDF file.

The templates were produced by GRACIOUS partners on the basis of their expertise, following the work previously completed in MARINA, GUIDEnano, NanoReg2 and caLIBRAte projects.

There are Excel workbooks for "Occupational Release and Exposure" and "Environmental Consumer Release" data. Within the workbook, data sheet can be used to report the NF Chemistry, NF Phys-Chem Characteristics, Matrix Characteristics, ECHA Descriptors, Contributing Exposure Scenario Details, Exposure Control Measures, Exposure Factors, Premises Details, Exposure Results, Instrument Characteristics, Exposure Measurement Results and/or Summary Release Results. Each scenario needs to be described by essential contextual information to allow a proper interpretation, comparison and reuse of results. Each row in a sheet contains the (meta) data referring to a unique measurement.

### Sheets available in the template

ECR (Environmental Consumer Release): Main data entry sheet to enter contextual information and measurement results.

QC-ECR: Quality criteria/score for Environmental Consumer Release calculated automatically.

Materials: List of Nanomaterials for which data is reported (Could be amended if needed).

List-ECR: List of drop-down validation data fields (Could be amended if needed).

This Excel workbook contains one GRACIOUS template for logging (meta) data on 'Environmental Consumer Release' measurements.

For logging (meta) data on 'Occupational Release and Exposure', please use different templates 'GRACIOUS\_template\_ORE'

### Data entry by

Project	Gracious
Work Package	WP2-Lifecycle: Human exposure & environmental release
Partner	LEITAT
Lead Scientist & contact for test:	E-mail address:
Date completed	2020-11-10

### Template

version	Template Wizard 2020-11-04
created by	GRACIOUS
	WP2-Lifecycle: Human exposure & environmental release

## Data similarity - eNanoMapper



## Presentation structure


- An overview of the GRACIOUS Framework
  - Examples grouping hypotheses
  - Example Integrated Approaches to Testing and Assessment
  - Similarity
  - Database links
  - Quality
  - Blueprint
-

# Data quality assessment methodology

Developed methodology to assess data quality aimed at reducing as much as possible the need of expert judgment.

The methodology takes into account the following criteria:

- **data completeness;**
- **data reliability;**
- **data relevance;**
- **data adequacy.**
- Scores are calculated for each of these criteria and those are aggregated into a **quality score** and a **completeness score**.



# Data quality assessment methodology

The last step involves the assignment of final data quality and completeness scores to a traffic light system.


Green – data high quality

Yellow – data is sufficient quality, but needs further consideration to be used for a specific task

Red – data is of insufficient quality.

The whole process can be automatised.


Data quality is highlighted on eNanoMapper user interface and/or in templates when uploading/downloading data from the database.



## Presentation structure

- An overview of the GRACIOUS Framework
  - Examples grouping hypotheses
  - Example Integrated Approaches to Testing and Assessment
  - Similarity
  - Database links
  - Quality
  - Blueprint
-





# gracious blueprint 0.1

This tool is used to test the gracious framework and blueprint.

[Learn more »](#)

## Getting started

To use this tool and get started you will need an account.

[Ask for an account »](#)

If you already have an account please:

[Login »](#)

## Project

This tool is used within the GRACIOUS project funded from the European Union's H2020 Framework Programme under grant agreement N°760840

[GRACIOUS project »](#)

## Development

This tool is developed using ThinkWorks Intelligent Objects engine.

[ThinkWorks »](#)





## Target nanoform(s)

Ag nanofibres 

+

Characteristics

Constituents (1)

Identification

Physical properties


Phys chem assays [PC] (1)

Environmental assays [EN]

Eco toxicity assays [EC]

Human health assays [HH]

Physico-chemical properties [OECD Harmonised Templates 1 to 23-5 and 101 to 113]


Scanning Electron Microscopy (1) 

+

-- select --

Dynamic Light Scattering (DLS)  
Small rotating Drum (SRD)  
Vortex Shaker (VS)  
Transmission Electron Microscopy (TEM)  
Brunauer–Emmett–Teller method (BET)  
Volumetric Centrifugation Method (VCM)  
ElectroSpray–Differential Mobility Analysis (ES-DMA)  
Sears titration ()  
X-ray Photoelectron Spectroscopy (XPS)  
Helium pycnometry ()  
Analytical Ultracentrifugation (AUC)  
CHN-Analysis (CHN)  
Inductively Coupled Plasma Mass Spectrometry (ICP-MS)  
X-ray diffraction (XRD)  
Screening batch dissolution test ()  
Continuous Flow System (CFS)  
Electrophoretic Light Scattering (ELS)  
Thermogravimetric Analysis/Mass Spectrometry (TGA-MS)  
Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES)  
Scanning Electron Microscopy (SEM)



[Case](#) [What they are](#) [Life cycle](#) [Where they go](#) **[Grouping](#)****Pooring** Nano fibre suspension disposed toward WWTP • Transform:  +**General info**Name: 

Testing strategy: Tier 2

**Grouping context**

- (1) Contributing Scenario (CS): [Adding Ag nanofibres to suspension](#)
- (2) Target nanoform (NF): [Ag nanofibres](#)
- (3) Surrounding medium: [Factory hall](#) | [air medium](#)

**POS** 'EXP-OCC-I-D'**POS** 'H-I-1'

MIS 'H-I-2'

MIS 'H-I-3'

MIS 'H-I-4'

MIS 'H-I-5'

MIS 'H-O-1A'

MIS 'H-O-1B'

MIS 'H-O-1C'

MIS 'H-D-2'

MIS 'H-D-3'

MIS 'H-D-1'

NYI 'H-D-4'

MIS 'TRANSPORT'

**Hypothesis H-I-1 (Lead: HWU)**

Respirable, biopersistent, rigid HARN: Following inhalation, long-term pulmonary retention of particles can occur resulting in lung toxicity.

**Potential for inhalation exposure**Aerodynamic diameter [nm]: **Assay result(s) found:**

- Scanning Electron Microscopy: [ PC\_GRANULOMETRY:EP\_AERODYNAMIC\_EQ\_SPHERE\_DIAMETER ] = 200.0-nm

**Deposition in the alveolar region of the lung**Dissolution of NF in lung lining fluid is: **Tier 2:** *In vitro* dissolution assay in lung lining fluid (pH 7.4)**Translocation to the plural cavity**Dissolution of NF in lysosomal fluid is: Average fibre length in  $\mu\text{m}$ : **Tier 2:** NF size measurements by TEM/SEM (ISO/TS 11888:2017) from an airborne dispersion of the materialAre NF fibres rigid with a needle like morphology? **Tier 2, 3:** *In vitro* incubation with macrophages 'Biologically stiff'-experimental, morphological assessment and size measurements after *in vitro* incubation with macrophages, degree of change from modelled

Incomplete uptake by alveolar macrophages, failed clearance.

Does NF cause frustrated phagocytosis? **Tier 2:** *In vitro* incubation with macrophages**Acute**

- Markers of lysosomal disruption and frustrated phagocytosis
- Cytotoxicity
- Pro-inflammatory markers

**Chronic**

- Granuloma formation

Group as poorly soluble, rigid HARN with potential to cause lung hazard

## Current status


- ✓ Hypotheses
  - Pre-defined list complete
  - User-defined template complete
- ✓ IATAs
  - Human complete
  - Environment complete

- ✓ Blueprint of software
  - Machine readable and open access
- ✓ Integrates hypotheses, IATAs and data sources
- ✓ Software undergoing internal testing

- Similarity methodology
- Quality criteria incorporation
- Blueprint and Framework testing
- Guidance document editing

There is still time to  
get involved in  
testing the  
GRACIOUS IATAs  
and Framework  
using your own case  
studies

## Detailed form



# Justification criteria are purpose specific. i.e. less stringent for SbD than for RA or legislation



# Thank you!

We look forward to hearing your ideas

Vicki Stone

[v.stone@hw.ac.uk](mailto:v.stone@hw.ac.uk)

[info@h2020gracious.eu](mailto:info@h2020gracious.eu)

[www.h2020gracious.eu](http://www.h2020gracious.eu)

